Euonymus alatus (Thunb.) Siebold Prevents Osteoclast Differentiation and Osteoporosis

• Published in: Nutrients Vol. 15; no. 18; p. 3996
• Main Authors: Lee, Sung-Ju, Jang, Seon-A, Kim, Seong Cheol, Gu, Dong Ryun, Yang, Hyun, Ryuk, Jin Ah, Ha, Hyunil
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 15-09-2023; MDPI
• Subjects: Antibodies; Bone diseases; bone loss; Chinese medicine; Euonymus alatus (Thunb.) Siebold; Herbal medicine; Kinases; Ligands; Osteoporosis; ovariectomy; Proteins; Tumor necrosis factor-TNF; United States > US; South Korea; Japan
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu15183996

Euonymus alatus (Thunb.) Siebold, a traditional medicinal plant, has been used in China and several other Asian countries to address a variety of health concerns. The extensive research conducted on E. alatus is driven by its diverse pharmacological applications. However, its biological effects on osteoclastogenesis and osteoporosis have not been previously studied. In this research, we investigated the impact of an ethanolic extract of E. alatus (EEEA) on osteoclast differentiation and function as well as estrogen deficiency-induced bone loss. We found that EEEA inhibits osteoclast differentiation by downregulating the expression of the receptor activator of nuclear factor-κB ligand (RANKL) in osteoclast-supporting cells and by directly impeding RANKL-mediated signaling pathways for osteoclastogenesis in precursor cells. In addition, EEEA inhibited the bone-resorptive function of mature osteoclasts in vitro. Furthermore, oral administration of EEEA significantly alleviated bone loss in an ovariectomy-induced osteoporosis mouse model. Additionally, we identified phytochemicals in EEEA that have suppressive effects on osteoclast differentiation and bone loss. Collectively, these results suggest that EEEA holds potential as a biotherapeutic candidate for anti-postmenopausal osteoporosis.